TLR7 and neoplasm: Emerging platforms integrate innate immune activation through TLR7 (Toll-like receptor 7)-agonist ISACs (Immune-Stimulating Antibody Conjugates) that conditionally stimulate myeloid cells upon tumour recognition (58) while surface-engineered NK cells conjugated with hydrophobic ADCs enable spatially controlled dual chemo-immunotherapy (59).